The lead candidate in our small-molecule portfolio is S-pindolol benzoate (ACM-001.1). Described as an Anabolic Catabolic Transforming Agent¹, S-pindolol influences several  pathways critical to the development of cachexia and muscle wasting. This class of agent has multiple pharmacological effects that result in:esult in:

•  Reduction in catabolism and the expenditure of energy

•  Increase in anabolism

•  Increase of appetite and reduced fatigue

Ultimately, this treatment method has the potential to improve patient quality of life in patients with cachexia and other conditions associated with muscle wasting disorders including weight loss during and after GLP-1RA therapy.

¹Pötsch MS, Tschirner A, Palus S, von Haehling S, Doehner W, Beadle J, Coats AJ, Anker SD, Springer J. The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. J Cachexia Sarcopenia Muscle. 2014 Jun;5(2):149-58